Vetcare spins out drug arm as AI reshapes veterinary pipeline
Finnish veterinary group Vetcare has separated its drug-development arm and launched a €240,000 AI project to assess early-stage ideas, seeking faster partnerships, clearer financing and a more disciplined route from scientific research to exportable animal-health products.
Vetcare has carved out its drug-development arm into a separate company in a bid to sharpen strategy, accelerate partnerships and make financing more transparent. The Finnish veterinary group is now pairing that structural change with an artificial-intelligence project aimed at sifting earlier-stage ideas more systematically, a sign that it wants to move faster in a sector where development is slow, regulated and capital-intensive. For animal-health companies, the experiment matters because it speaks to how smaller groups can turn scientific know-how into exportable products without bearing every risk alone.
Vetcare Innovations, based in Helsinki, was created in 2025 and is led by Veli-Matti Riipinen. The business sits within Vetcare but is designed to give drug development its own management, process and partner network, while helping the parent company keep commercial and financing flows clearer.
Riipinen says the unit is not trying to replace human judgement with software. Instead, it has launched a project backed by a €120,000 Business Finland grant, with total funding of about €240,000, to test whether AI can assess veterinary drug concepts more systematically by weighing medical need, commercial logic and scientific evidence.
Vetcare already has two original products on the market, Zenalpha for dogs and Lystralin, and exports to more than 30 countries. The company, which has spent years building molecules and securing approvals, believes the new structure can support both modestly sized products and larger international opportunities.
"This news service is powered by an AI tool that curates and enhances the content related to animal health. The articles provided are for informational purposes only and should not be considered professional or veterinary advice. The content presented does not reflect the views or opinions of Stonehaven Analytics."